Abstract
Background We have carried out an analysis to evaluate the influence of hospital teaching status on the outcomes of individuals hospitalized with MDS. Methods The National Inpatient Sample (NIS) dataset for the years 2019-2020 was employed to identify individuals who were hospitalized with a primary diagnosis of MDS. These patients were then categorized into two groups: those who were hospitalized in teaching hospitals and those who were hospitalized in non-teaching hospitals. Multivariate regression analysis was performed to calculate the primary and secondary outcomes. Results In the years 2019 and 2020, a total of 17,000 patients were hospitalized with myelodysplastic syndromes (MDS). Among these, 24.05% (4,080) were admitted to non-teaching hospitals, while 75.94% (12,920) were admitted to teaching hospitals. Patients admitted to teaching hospitals had a higher likelihood of mortality (OR 1.84, 95% CI 1.03-3.27, P=0.037), as well as increased lengths of stay (+3.58 Days, 95% CI 2.82-4.34, P<0.001)and total hospitalization costs (+USD 66818, 95% CI 50528-83108, P<0.001). Additionally, patients in teaching hospitals had a higher incidence of acute respiratory failure (6.81% vs 4.4%), acute kidney injury (23.89% vs 17.72%), hematopoietic stem cell transplantation (14.36% vs 0.61%), and febrile neutropenia (11.03% vs 5.86%). However, patients in teaching hospitals had a lower incidence of anemia (41.86% vs 48.53%) and blood transfusions (38.8% vs 55.37%). Conclusion Individuals who were admitted to teaching hospitals with Myelodysplastic Syndromes (MDS) exhibited a notably higher mortality rate, as well as an extended length of stay and a corresponding increase in the total cost of hospitalization. Patients in teaching hospitals were also at risk for acute kidney injury, acute respiratory failure and febrile neutropenia.